Connect with us

Hi, what are you looking for?

Stock

J&J explores takeover bid for Intra-Cellular Therapies, Bloomberg reports

Investing.com– Johnson & Johnson (NYSE:JNJ) is considering a bid to acquire biopharmaceutical company Intracellular Th (NASDAQ:ITCI), Bloomberg News reported on Sunday, citing sources familiar with the matter.

A deal between both parties could be reached as early as this week, the Bloomberg report stated. Intra-Cellular has a market value of roughly $10 billion.

Intra-Cellular Therapies is best known for Caplyta, its FDA-approved treatment for schizophrenia and bipolar disorders. The potential acquisition could help J&J expand its neuroscience portfolio and offset revenue challenges anticipated from patent expirations on its blockbuster drugs.

The discussions are said to be in an early stage, and no final decision has been made. There is no guarantee that negotiations will lead to a formal deal, according to the sources, according to the report.

Intra-Cellular shares had surged nearly 15% on Friday, reflecting investor anticipation of a potential deal.

J&J has remained active in pursuing high-growth therapeutic areas, aiming to solidify its pharmaceutical division’s growth amidst intensifying competition.

This post appeared first on investing.com

    You May Also Like

    Latest News

    A group of more than 60 former Democratic and Republican attorneys general sent a new letter to Senate leaders Thursday urging the confirmation of...

    Stock

    Investing.com — RBC Capital Markets in a note dated Thursday has downgraded Swatch Group (SIX:UHR) to an “underperform” rating, citing structural and cyclical challenges...

    Stock

    By Rocky Swift TOKYO (Reuters) -Japan’s Fuji Media said on Monday its chairman and the head of its TV unit would step down immediately...

    Stock

    Investing.com — Universal Music Group (AS:UMG) and Spotify (NYSE:SPOT) have announced a new multi-year deal for recorded music and publishing, the companies announced in...



    Disclaimer: Techreportdiversity.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 Techreportdiversity.com